Infinity Pharmaceuticals, Inc.
http://www.infi.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Infinity Pharmaceuticals, Inc.
Time For Oral Incretins To Prove Their Worth
Several crucial trial readouts in diabetes and obesity will come this year and next, and the stakes are high.
Finance Watch: Biopharma Firms Get Ahead Of Q3 Updates With Restructuring Reveals
Restructuring Edition: Biogen and Sana add to their layoff totals. Exscientia announced R&D program cuts while Syros, PTC, AM-Pharma, Societal CDMO, Nighthawk and Kinnate revealed layoffs to conserve cash. Also, Impel is exploring strategic options and Applied Molecular Transport will disappear in a merger with Cyclo.
Finance Watch: UroGen Accesses Cash After Phase III Bladder Cancer Success
Public Company Edition: UroGen raised $120m in a private placement of ordinary shares. Also, Verrica entered into a debt financing for up to $125m upon approval of Ycanth for molluscum contagiosum and job cuts were announced by Homology, Mersana, Infinity and others.
Infinity And MEI Re-evaluate Business Plans After Merger Falls Through
MEI shareholders declined to approve the all-stock merger that would have combined the companies’ cancer pipelines.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
- Molecular Diversity
-
Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice